139 related articles for article (PubMed ID: 33989088)
21. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
22. Safety and Effectiveness of Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation and Anemia: A Retrospective Cohort Study.
Wang CL; Wu VC; Huang YT; Kuo CF; Chu PH; Chen YL; Wen MS; Chang SH
J Am Heart Assoc; 2019 May; 8(9):e012029. PubMed ID: 31020896
[TBL] [Abstract][Full Text] [Related]
23. Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II).
Steinberg BA; Shrader P; Pieper K; Thomas L; Allen LA; Ansell J; Chan PS; Ezekowitz MD; Fonarow GC; Freeman JV; Gersh BJ; Kowey PR; Mahaffey KW; Naccarelli GV; Reiffel JA; Singer DE; Peterson ED; Piccini JP;
J Am Heart Assoc; 2018 Feb; 7(4):. PubMed ID: 29453305
[TBL] [Abstract][Full Text] [Related]
24. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
[TBL] [Abstract][Full Text] [Related]
25. Predictors of Major Bleeding Among Working-Age Adults with Atrial Fibrillation: Evaluating the Effects of Potential Drug-drug Interactions and Switching from Warfarin to Non-vitamin K Oral Anticoagulants.
Feng X; Sambamoorthi U; Innes K; Castelli G; LeMasters T; Xiong L; Williams MU; Tan X
Cardiovasc Drugs Ther; 2018 Dec; 32(6):591-600. PubMed ID: 30315487
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation.
Lee HF; Chan YH; Chang SH; Tu HT; Chen SW; Yeh YH; Wu LS; Kuo CF; Kuo CT; See LC
J Am Heart Assoc; 2019 Mar; 8(5):e011112. PubMed ID: 30834802
[TBL] [Abstract][Full Text] [Related]
27. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
Steffel J; Verhamme P; Potpara TS; Albaladejo P; Antz M; Desteghe L; Haeusler KG; Oldgren J; Reinecke H; Roldan-Schilling V; Rowell N; Sinnaeve P; Collins R; Camm AJ; Heidbüchel H;
Eur Heart J; 2018 Apr; 39(16):1330-1393. PubMed ID: 29562325
[TBL] [Abstract][Full Text] [Related]
28. Bleeding and thromboembolism due to drug-drug interactions with non-vitamin K antagonist oral anticoagulants-a Swedish, register-based cohort study in atrial fibrillation outpatients.
Holm J; Mannheimer B; Malmström RE; Eliasson E; Lindh JD
Eur J Clin Pharmacol; 2021 Mar; 77(3):409-419. PubMed ID: 33029651
[TBL] [Abstract][Full Text] [Related]
29. Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data.
Kohsaka S; Katada J; Saito K; Jenkins A; Li B; Mardekian J; Terayama Y
Open Heart; 2020; 7(1):e001232. PubMed ID: 32341789
[TBL] [Abstract][Full Text] [Related]
30. The Risk of Gastrointestinal Bleeding between Non-Vitamin K Antagonist Oral Anticoagulants and Vitamin K Antagonists in the Asian Atrial Fibrillation Patients: A Meta-Analysis.
Yang KT; Sun WC; Tsai TJ; Tsay FW; Chen WC; Cheng JS
Int J Environ Res Public Health; 2020 Dec; 18(1):. PubMed ID: 33375495
[No Abstract] [Full Text] [Related]
31. Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis.
Caldeira D; Rodrigues FB; Barra M; Santos AT; de Abreu D; Gonçalves N; Pinto FJ; Ferreira JJ; Costa J
Heart; 2015 Aug; 101(15):1204-11. PubMed ID: 26037103
[TBL] [Abstract][Full Text] [Related]
32. Differences in knowledge among patients with atrial fibrillation receiving non-vitamin K antagonist oral anticoagulants and vitamin K antagonists.
Konieczyńska M; Sobieraj E; Bryk AH; Dębski M; Polak M; Podolec P; Małecka B; Pająk A; Desteghe L; Heidbuchel H; Undas A
Kardiol Pol; 2018; 76(7):1089-1096. PubMed ID: 29528483
[TBL] [Abstract][Full Text] [Related]
33. Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011-2016.
Maura G; Billionnet C; Drouin J; Weill A; Neumann A; Pariente A
BMJ Open; 2019 Apr; 9(4):e026645. PubMed ID: 31005934
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness and safety of non-vitamin-K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients with thrombocytopenia.
Wang CL; Wu VC; Lee CH; Kuo CF; Chen YL; Chu PH; Chen SW; Wen MS; See LC; Chang SH
J Thromb Thrombolysis; 2019 May; 47(4):512-519. PubMed ID: 30565148
[TBL] [Abstract][Full Text] [Related]
35. Changes in Oral Anticoagulation Therapy over One Year in 51,000 Atrial Fibrillation Patients at Risk for Stroke: A Practice-Derived Study.
Hohnloser SH; Basic E; Nabauer M
Thromb Haemost; 2019 Jun; 119(6):882-893. PubMed ID: 30900220
[TBL] [Abstract][Full Text] [Related]
36. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.
Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K;
Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811
[TBL] [Abstract][Full Text] [Related]
37. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort.
Huisman MV; Ma CS; Diener HC; Dubner SJ; Halperin JL; Rothman KJ; Teutsch C; Schoof N; Kleine E; Bartels DB; Lip GY;
Europace; 2016 Sep; 18(9):1308-18. PubMed ID: 27335063
[TBL] [Abstract][Full Text] [Related]
38. Treatment Changes among Users of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation.
Hellfritzsch M; Husted SE; Grove EL; Rasmussen L; Poulsen BK; Johnsen SP; Hallas J; Pottegård A
Basic Clin Pharmacol Toxicol; 2017 Feb; 120(2):187-194. PubMed ID: 27580086
[TBL] [Abstract][Full Text] [Related]
39. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary.
Steffel J; Verhamme P; Potpara TS; Albaladejo P; Antz M; Desteghe L; Georg Haeusler K; Oldgren J; Reinecke H; Roldan-Schilling V; Rowell N; Sinnaeve P; Collins R; Camm AJ; Heidbüchel H;
Europace; 2018 Aug; 20(8):1231-1242. PubMed ID: 29562331
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation With Hypertrophic Cardiomyopathy: A Nationwide Cohort Study.
Jung H; Yang PS; Jang E; Yu HT; Kim TH; Uhm JS; Kim JY; Pak HN; Lee MH; Joung B; Lip GYH
Chest; 2019 Feb; 155(2):354-363. PubMed ID: 30472021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
